In 2017, the CANTOS (Canakinumab ANti-inflammatory Thrombosis Outcomes Study) clinical trial evaluated the effect of a neutralizing anti-IL-1β antibody (Ab) (canakinumab) in patients with atherosclerosis prone to cardiovascular events and made the serendipitous observation that IL-1β blockade significantly reduced LC incidence and mortality [24]. Here, IL1B is linked to deep vein thrombosis.